What is a reasonable price for society to pay to give a patient with cancer 1 extra year of life without tumor growth?
Certainly not $2.2 million. According to Almutairi and colleagues,1 this is how much it would cost to add 1 good year of progression-free survival to a patient’s life using talimogene laherparepvec plus ipilimumab. The authors make a valuable contribution by rigorously applying the tools of cost-effectiveness analysis to understand whether novel but expensive treatments are really worth pursuing. The analysis suggests 3 important conclusions.
DiMagno SSP, Emanuel EJ. Pricing a Year of Progression-Free Survival: When Is the Cost of Cancer Drugs Unreasonable? JAMA Dermatol. 2019;155(1):15–16. doi:10.1001/jamadermatol.2018.3753
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: